Bet v 1-specific immunoglobulin

Bet v 1-specific immunoglobulins, encompassing both membrane-bound B-cell receptors (BCRs) and secreted antibodies (IgE, IgG), are the central molecular components of birch pollen allergy (Galson et al., 2020, J Allergy Clin Immunol). Bet v 1 is the primary allergen from Betula verrucosa, and in sensitized individuals, the production of Bet v 1-specific IgE leads to its loading onto high-affinity receptors on mast cells and basophils (UniProt P15494). Subsequent exposure to the allergen causes cross-linking of these IgE-BCR complexes, triggering the degranulation and release of inflammatory mediators responsible for allergic rhinitis and asthma symptoms (Valenta et al., 2010, Immunol Rev). Therapeutic interventions focus on modulating these immunoglobulins, either by neutralizing circulating IgE with monoclonal antibodies like omalizumab or by inducing a shift toward "blocking" IgG4 antibodies through allergen immunotherapy (AIT) (Shamji et al., 2011, J Allergy Clin Immunol). Recent advancements include the development of recombinant monoclonal antibody cocktails, such as REGN5713/5714/5715, designed to compete with IgE for allergen binding, providing rapid protection against allergic reactions (Regeneron Pharmaceuticals, 2023). Understanding the BCR repertoire is crucial for developing next-generation vaccines and biologics aimed at inducing long-term immune tolerance.

Other names

Bet v 1-specific B-cell receptorBet v 1-specific antibodyBirch pollen allergen-specific IgEBirch pollen allergen-specific IgGBet v 1-specific BCR

Neutralization of allergen-specific IgE, induction of blocking IgG4 antibodies, and competitive inhibition of allergen binding to B-cell receptors to prevent mast cell degranulation.